I too am curious who else would use this outside of potential Leronlimab patients? Maybe maraviroc or other CCR5 drugs in development, but I can't see this being anything significant prior to Leronlimab approval, and view this more as a way to offset a little pre-screening costs while using product that would likely be not be used otherwise.

You stated the $400 costs which is what I recalled from initial IncellDX PR, so I'm curious how much revenue this will bring in? I can't see it being much, but any revenue helps and is welcomed prior to sales. I'm curious if they decide to charge (at cost) for the 'Expanded Access' and wonder if this revenue would all be lumped together in the financial statements?